Apollo Endosurgery Inc (NASDAQ:APEN)’s share price reached a new 52-week low on Friday following a weaker than expected earnings announcement. The company traded as low as $3.66 and last traded at $3.99, with a volume of 13200 shares. The stock had previously closed at $5.75.
The biotechnology company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.11). The firm had revenue of $14.14 million for the quarter, compared to analysts’ expectations of $16.21 million. Apollo Endosurgery had a negative return on equity of 58.61% and a negative net margin of 46.55%.
A number of research firms have recently weighed in on APEN. Northland Securities cut Apollo Endosurgery from an “outperform” rating to a “market perform” rating in a report on Thursday, August 9th. Roth Capital reissued a “neutral” rating and issued a $9.50 price target on shares of Apollo Endosurgery in a report on Tuesday, July 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $6.83.
In other Apollo Endosurgery news, major shareholder Stonepine Capital, L.P. bought 300,000 shares of the company’s stock in a transaction that occurred on Friday, November 2nd. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $1,500,000.00. Following the completion of the purchase, the insider now owns 2,877,996 shares of the company’s stock, valued at approximately $14,389,980. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 52.80% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in APEN. BlackRock Inc. increased its stake in Apollo Endosurgery by 42.4% in the second quarter. BlackRock Inc. now owns 22,768 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 6,775 shares during the last quarter. Renaissance Technologies LLC increased its stake in Apollo Endosurgery by 30.9% in the second quarter. Renaissance Technologies LLC now owns 45,300 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 10,700 shares during the last quarter. Ardsley Advisory Partners increased its stake in Apollo Endosurgery by 25.0% in the second quarter. Ardsley Advisory Partners now owns 50,000 shares of the biotechnology company’s stock valued at $349,000 after purchasing an additional 10,000 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Apollo Endosurgery in the first quarter valued at $378,000. Finally, JPMorgan Chase & Co. increased its stake in Apollo Endosurgery by 411.1% in the third quarter. JPMorgan Chase & Co. now owns 58,427 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 46,995 shares during the last quarter. Hedge funds and other institutional investors own 38.93% of the company’s stock.
The company has a market cap of $133.68 million, a P/E ratio of -1.97 and a beta of 0.34. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.60.
COPYRIGHT VIOLATION WARNING: This story was first reported by Macon Daily and is the property of of Macon Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://macondaily.com/2018/11/11/apollo-endosurgery-apen-hits-new-12-month-low-on-disappointing-earnings.html.
About Apollo Endosurgery (NASDAQ:APEN)
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope.
See Also: What is a Swap?
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.